TechHR
ex
L&D
UNPLUGGED
Sphere
About Us • Contact Us
People Matters ANZ
People Matters Logo
Login / Signup
People Matters Logo
Login / Signup
  • Current
  • Top Stories
  • News
  • Magazine
  • Research
  • Events
  • Videos
  • Webinars
  • Podcast

© Copyright People Matters Media Pte. Ltd. All Rights Reserved.

 

 

  • HotTopic
    HR Folk Talk FutureProofHR
  • Strategy
    Leadership Csuite StrategicHR EmployeeRelations BigInterview
  • Recruitment
    Employer Branding Appointments Permanent Hiring Recruitment
  • Performance
    Skilling PerformanceMgmt Compensation Benefits L&D Employee Engagement
  • Culture
    Culture Life@Work Diversity Watercooler SheMatters
  • Tech
    Technology HR Technology Funding & Investment Startups Metaverse
  • About Us
  • Advertise with us
  • Become a sponsor
  • Contact Us
  • Feedback
  • Write For Us

Follow us:

Privacy Policy • Terms of Use

© Copyright People Matters Media Pte. Ltd. All Rights Reserved.

People Matters Logo
  • Current
  • Top Stories
  • News
  • Magazine
  • Research
  • Events
  • Videos
  • Webinars
  • Podcast
Login / Signup

Categories:

  • HotTopic
    HR Folk Talk FutureProofHR
  • Strategy
    Leadership Csuite StrategicHR EmployeeRelations BigInterview
  • Recruitment
    Employer Branding Appointments Permanent Hiring Recruitment
  • Performance
    Skilling PerformanceMgmt Compensation Benefits L&D Employee Engagement
  • Culture
    Culture Life@Work Diversity Watercooler SheMatters
  • Tech
    Technology HR Technology Funding & Investment Startups Metaverse
Kriya Therapeutics secures $270 million funding; to push for growth acceleration

News • 17th May 2022 • 2 Min Read

Kriya Therapeutics secures $270 million funding; to push for growth acceleration

TechnologyFunding & Investment#Hiring

Author: Ajinkya Salvi Ajinkya Salvi
7.1K Reads
The funding will be utilised to expand teams, advance the gene therapy research and scale its machine-learning based technology.

Kriya Therapeutics has announced that it has secured $270 million in a Series C financing round, led by Patient Square Capital. The latest funding brings the total capital raised by US-based biotech company to about $450 million.

The existing investors who participated included Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT and Transhuman Capital.

The funding will be used to support the advancement of its diverse pipeline and continued scaling of its engineering, manufacturing, and computational platforms, as per the company's statement.

Jim Momtazee, Managing Partner of Patient Square Capital and Kriya Board Member, “Kriya has made tremendous strides over the past few years, attracting world-class talent, expanding its pipeline, and scaling the infrastructure necessary to unlock the full potential of gene therapy. We believe the company has the potential to be the clear leader in the evolving gene therapy field, consistent with Patient Square Capital’s focus to build and support category leading companies in health care.”

The biotech startup, who specialises in gene therapy, was founded in 2019 by Shankar Ramaswamy, Roger Jeffs and John Fraser Wright. For the uninitiated, it billed itself as a next-generation gene therapy company focused on designing & developing treatments for highly prevalent and severe chronic conditions, like diabetes and obesity. Additonally, the company would be expanding their team in the US as well globally. Currently they have 160 employers working tirelessly in labs and offices in the San Francisco Bay Area, USA. 

The biotech startup will also scale its machine learning-enabled technology and cloud computing platform called SIRVE. The platform supports the integration of large datasets generated by the company’s high throughput screening, next generation sequencing, and algorithmic data mining platforms, the company said in its release.

Shankar Ramaswamy, M.D, Co-Founder and Chief Executive Officer, said,“Kriya was founded to address the primary problems limiting the field, and I am proud of the progress we have made to date. This financing will support our continued growth as we advance our diverse pipeline into the clinic and further scale our core platforms, to achieve our ultimate vision of expanding the reach and unlocking the full potential of gene therapy as a modality.

The gene therapy is based on research led by Duke University’s Priya Kishnani, M.D., and Aravind Asokan, Ph.D., and contains five investigational programs for GSDs that have no existing FDA-approved treatments available, yet.

Read More

Did you find this article helpful?


You Might Also Like

TechDiversity marks decade of DEI progress

NEWS • 8th May 2025 • 2 Min Read

TechDiversity marks decade of DEI progress

DiversityTechnology#DEIB
Australia, New Zealand have highest ROI on genAI

NEWS • 17th Apr 2025 • 3 Min Read

Australia, New Zealand have highest ROI on genAI

Technology#Artificial Intelligence
Alphabet, Nvidia back Ilya Sutskever's SSI

NEWS • 15th Apr 2025 • 3 Min Read

Alphabet, Nvidia back Ilya Sutskever's SSI

TechnologyFunding & Investment
NEXT STORY: Amazon Australia welcomes employees’ dogs into the office

Trending Stories

  • design-thinking-hr

    Skype is dead: Did Microsoft's leadership let a billion-doll...

  • design-thinking-hr

    Keeping the C-suite in the C-suite - how do we reduce execut...

  • design-thinking-hr

    Return to office: the legalities

  • design-thinking-hr

    The trust factor: Why modern leaders can’t afford to overl...

People Matters Logo

Follow us:

Join our mailing list:

By clicking “Subscribe” button above, you are accepting our Terms & Conditions and Privacy Policy.

Company:

  • About Us
  • Advertise with us
  • Become a sponsor
  • Privacy Policy
  • Terms of Use

Contact:

  • Contact Us
  • Feedback
  • Write For Us

© Copyright People Matters Media Pte. Ltd. All Rights Reserved.

Get the latest Articles, Insight, News & Trends from the world of Talent & Work. Subscribe now!
People Matters Logo

Welcome Back!

or

Enter your registered email address to login

Not a user yet? Lets get you signed up!

A 5 digit OTP has been sent to your email address.

This is so we know it's you. Haven't received it yet? Resend the email or then change your email ID.

People Matters Logo

Welcome! Let's get you signed up...

Starting with the absolulte basics.

Already a user? Go ahead and login!

A 5 digit OTP has been sent to your email address.

This is so we know it's you. Haven't received it yet? Resend the email or then change your email ID.

Let's get to know you better

We'll never share your details with anyone, pinky swear.

And lastly...

Your official designation and company name.